BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 36612004)

  • 1. Stereotactic MR-Guided Adaptive Radiotherapy for Pancreatic Tumors: Updated Results of the Montpellier Prospective Registry Study.
    Bordeau K; Michalet M; Keskes A; Valdenaire S; Debuire P; Cantaloube M; Cabaillé M; Portales F; Draghici R; Ychou M; Assenat E; Mazard T; Samalin E; Gauthier L; Colombo PE; Carrere S; Souche FR; Aillères N; Fenoglietto P; Azria D; Riou O
    Cancers (Basel); 2022 Dec; 15(1):. PubMed ID: 36612004
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Stereotactic MR-Guided Radiotherapy for Pancreatic Tumors: Dosimetric Benefit of Adaptation and First Clinical Results in a Prospective Registry Study.
    Michalet M; Bordeau K; Cantaloube M; Valdenaire S; Debuire P; Simeon S; Portales F; Draghici R; Ychou M; Assenat E; Dupuy M; Gourgou S; Colombo PE; Carrere S; Souche FR; Aillères N; Fenoglietto P; Azria D; Riou O
    Front Oncol; 2022; 12():842402. PubMed ID: 35356227
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Stereotactic MR-guided on-table adaptive radiation therapy (SMART) for borderline resectable and locally advanced pancreatic cancer: A multi-center, open-label phase 2 study.
    Chuong MD; Lee P; Low DA; Kim J; Mittauer KE; Bassetti MF; Glide-Hurst CK; Raldow AC; Yang Y; Portelance L; Padgett KR; Zaki B; Zhang R; Kim H; Henke LE; Price AT; Mancias JD; Williams CL; Ng J; Pennell R; Raphael Pfeffer M; Levin D; Mueller AC; Mooney KE; Kelly P; Shah AP; Boldrini L; Placidi L; Fuss M; Jitendra Parikh P
    Radiother Oncol; 2024 Feb; 191():110064. PubMed ID: 38135187
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Stereotactic body radiation therapy for locally advanced and borderline resectable pancreatic cancer is effective and well tolerated.
    Chuong MD; Springett GM; Freilich JM; Park CK; Weber JM; Mellon EA; Hodul PJ; Malafa MP; Meredith KL; Hoffe SE; Shridhar R
    Int J Radiat Oncol Biol Phys; 2013 Jul; 86(3):516-22. PubMed ID: 23562768
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Stereotactic MR-Guided Radiotherapy for Liver Metastases: First Results of the Montpellier Prospective Registry Study.
    Bordeau K; Michalet M; Keskes A; Valdenaire S; Debuire P; Cantaloube M; Cabaillé M; Jacot W; Draghici R; Demontoy S; Quantin X; Ychou M; Assenat E; Mazard T; Gauthier L; Dupuy M; Guiu B; Bourgier C; Aillères N; Fenoglietto P; Azria D; Riou O
    J Clin Med; 2023 Feb; 12(3):. PubMed ID: 36769831
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term outcomes of induction chemotherapy and neoadjuvant stereotactic body radiotherapy for borderline resectable and locally advanced pancreatic adenocarcinoma.
    Mellon EA; Hoffe SE; Springett GM; Frakes JM; Strom TJ; Hodul PJ; Malafa MP; Chuong MD; Shridhar R
    Acta Oncol; 2015 Jul; 54(7):979-85. PubMed ID: 25734581
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Multi-Institutional Phase 2 Trial of Ablative 5-Fraction Stereotactic Magnetic Resonance-Guided On-Table Adaptive Radiation Therapy for Borderline Resectable and Locally Advanced Pancreatic Cancer.
    Parikh PJ; Lee P; Low DA; Kim J; Mittauer KE; Bassetti MF; Glide-Hurst CK; Raldow AC; Yang Y; Portelance L; Padgett KR; Zaki B; Zhang R; Kim H; Henke LE; Price AT; Mancias JD; Williams CL; Ng J; Pennell R; Pfeffer MR; Levin D; Mueller AC; Mooney KE; Kelly P; Shah AP; Boldrini L; Placidi L; Fuss M; Chuong MD
    Int J Radiat Oncol Biol Phys; 2023 Nov; 117(4):799-808. PubMed ID: 37210048
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High local failure rates despite high margin-negative resection rates in a cohort of borderline resectable and locally advanced pancreatic cancer patients treated with stereotactic body radiation therapy following multi-agent chemotherapy.
    Hill C; Sehgal S; Fu W; Hu C; Reddy A; Thompson E; Hacker-Prietz A; Le D; De Jesus-Acosta A; Lee V; Zheng L; Laheru DA; Burns W; Weiss M; Wolfgang C; He J; Herman JM; Meyer J; Narang A
    Cancer Med; 2022 Apr; 11(7):1659-1668. PubMed ID: 35142085
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Isotoxic high-dose stereotactic body radiotherapy integrated in a total multimodal neoadjuvant strategy for the treatment of localized pancreatic ductal adenocarcinoma.
    Bouchart C; Engelholm JL; Closset J; Navez J; Loi P; Gökburun Y; De Grez T; Mans L; Hendlisz A; Bali MA; Eisendrath P; Van Gestel D; Hein M; Moretti L; Van Laethem JL
    Ther Adv Med Oncol; 2021; 13():17588359211045860. PubMed ID: 34691244
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neoadjuvant Stereotactic Body Radiotherapy After Upfront Chemotherapy Improves Pathologic Outcomes Compared With Chemotherapy Alone for Patients With Borderline Resectable or Locally Advanced Pancreatic Adenocarcinoma Without Increasing Perioperative Toxicity.
    Hill CS; Rosati LM; Hu C; Fu W; Sehgal S; Hacker-Prietz A; Wolfgang CL; Weiss MJ; Burkhart RA; Hruban RH; De Jesus-Acosta A; Le DT; Zheng L; Laheru DA; He J; Narang AK; Herman JM
    Ann Surg Oncol; 2022 Apr; 29(4):2456-2468. PubMed ID: 35129721
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical outcomes of stereotactic magnetic resonance image-guided adaptive radiotherapy for primary and metastatic tumors in the abdomen and pelvis.
    Yoon SM; Luterstein E; Chu FI; Cao M; Lamb J; Agazaryan N; Low D; Raldow A; Steinberg ML; Lee P
    Cancer Med; 2021 Sep; 10(17):5897-5906. PubMed ID: 34288538
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dose escalated concurrent chemo-radiation in borderline resectable and locally advanced pancreatic cancers with tomotherapy based intensity modulated radiotherapy: a phase II study.
    Lewis S; Sastri SC; Arya S; Mehta S; Patil P; Shrivastava S; Phurailatpam R; Shrikhande SV; Engineer R
    J Gastrointest Oncol; 2019 Jun; 10(3):474-482. PubMed ID: 31183197
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Survival outcome after stereotactic body radiotherapy for locally advanced and borderline resectable pancreatic cancer: A systematic review and meta-analysis.
    Liu S; Liu Y; Yang J; Santos TD; Yang L; Li M; Jiang Q; Ma C
    Transl Oncol; 2021 Aug; 14(8):101139. PubMed ID: 34091293
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Role of Stereotactic Body Radiation Therapy for Pancreatic Cancer: A Single-Institution Experience.
    Moningi S; Dholakia AS; Raman SP; Blackford A; Cameron JL; Le DT; De Jesus-Acosta AM; Hacker-Prietz A; Rosati LM; Assadi RK; Dipasquale S; Pawlik TM; Zheng L; Weiss MJ; Laheru DA; Wolfgang CL; Herman JM
    Ann Surg Oncol; 2015 Jul; 22(7):2352-8. PubMed ID: 25564157
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Stereotactic MR-Guided Online Adaptive Radiation Therapy (SMART) for Ultracentral Thorax Malignancies: Results of a Phase 1 Trial.
    Henke LE; Olsen JR; Contreras JA; Curcuru A; DeWees TA; Green OL; Michalski J; Mutic S; Roach MC; Bradley JD; Parikh PJ; Kashani R; Robinson CG
    Adv Radiat Oncol; 2019; 4(1):201-209. PubMed ID: 30706029
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Stereotactic body radiation therapy for locally advanced pancreatic cancer.
    Jung J; Yoon SM; Park JH; Seo DW; Lee SS; Kim MH; Lee SK; Park DH; Song TJ; Ryoo BY; Chang HM; Kim KP; Yoo C; Jeong JH; Kim SC; Hwang DW; Lee JH; Song KB; Jo YY; Park J; Kim JH
    PLoS One; 2019; 14(4):e0214970. PubMed ID: 30978229
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Consolidatory ablative stereotactic body radiation therapy after induction chemotherapy for unresectable pancreatic cancer: A single center experience.
    Lee HI; Kang HC; Chie EK
    Front Oncol; 2022; 12():974454. PubMed ID: 36505838
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ablative 5-Fraction Stereotactic Magnetic Resonance-Guided Radiation Therapy With On-Table Adaptive Replanning and Elective Nodal Irradiation for Inoperable Pancreas Cancer.
    Chuong MD; Bryant J; Mittauer KE; Hall M; Kotecha R; Alvarez D; Romaguera T; Rubens M; Adamson S; Godley A; Mishra V; Luciani G; Gutierrez AN
    Pract Radiat Oncol; 2021; 11(2):134-147. PubMed ID: 32947042
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multi-Institutional Outcomes of Patients Aged 75 years and Older With Pancreatic Ductal Adenocarcinoma Treated With 5-Fraction Ablative Stereotactic Magnetic Resonance Image-Guided Adaptive Radiation Therapy (A-SMART).
    Bryant JM; Palm RF; Herrera R; Rubens M; Hoffe SE; Kim DW; Kaiser A; Ucar A; Fleming J; De Zarraga F; Hodul P; Aparo S; Asbun H; Malafa M; Jimenez R; Denbo J; Frakes JM; Chuong MD
    Cancer Control; 2023; 30():10732748221150228. PubMed ID: 36598464
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pancreatic cancer outcome-local treatment with radiation using MRI-LINAC.
    Almog G; Pfeffer RM; Zalmanov S; Grinberg V; Lipsky Y; Chernomordikov E; Levin D; Apter S; Arsenault O; Epstein D; Tamimi Q; Hod K; Limon D; Golan T; Ben-Aharon I; Lawrence YR; Ben-David MA
    Front Oncol; 2023; 13():1289919. PubMed ID: 38074644
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.